iBio Inc (IBIO):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:iBio Inc (IBIO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12326
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
iBio Inc (iBio) is a biotechnology company that develops and manufactures plant made pharmaceutical products. The company provides products such as biotherapeutics and vaccines. It has its applications in ibiolaunch platform, which is a transformative technology for the production of monoclonal antibodies, other therapeutic proteins and vaccines. iBio is developing therapeutic product for the treatment of idiopathic pulmonary fibrosis, systemic scleroderma and other fibrotic diseases, and others. The company’s IBIO-CFB03 is helpful for the treatment of idiopathic pulmonary fibrosis, fibrotic diseases and systemic sclerosis, among others. It collaborates with medical universities for its research and development activities. iBio is headquartered in New York, the US.

iBio Inc (IBIO) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
iBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
iBio Inc, Pharmaceuticals & Healthcare, Deal Details 13
Partnerships 13
iBio Enters into Agreement with AzarGen Biotechnologies 13
Texas A&M University Enters into Agreement with iBio 14
iBio Amends Agreement with Medical University of South Carolina 15
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 16
iBio Enters into Agreement with Novici Biotech 17
Licensing Agreements 18
iBio Amends Licensing Agreement with US University 18
iBio Enters into Licensing Agreement with University of Pittsburgh 19
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 20
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 22
iBio Extends Licensing Agreement with Fraunhofer 23
iBio Extends its Licensing Agreement with Bio-Manguinhos 24
Equity Offering 25
iBio Raises USD16 Million in Public Offering of Shares 25
iBio Raises USD4.5 Million in Public Offering of Shares 26
iBio to Raise Funds in Public Offering of Shares 27
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 28
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 30
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 31
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 32
iBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 33
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 34
iBio Raises USD10 Million in Private Placemet of Shares 35
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 36
Ibio Completes Public Offering Of Units For US$4 Million 37
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For US$10 Million 38
iBio Inc – Key Competitors 39
iBio Inc – Key Employees 40
iBio Inc – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 42
Legal and Regulatory 42
Nov 06, 2017: iBio Initiates Litigation Against Fraunhofer-Gesellschaft in Delaware Chancery Court 42
Product News 43
Mar 14, 2018: iBio Selects Lead Candidate for its Fibrosis Therapeutics Program 43
03/14/2018: iBio Selects Lead Candidate for its Fibrosis Therapeutics Program 44
Mar 07, 2018: iBio Expands Antibody Development and Production Services to Include Fc Fusion Therapeutics 45
Other Significant Developments 46
Oct 30, 2017: iBio CDMO President to Co-Chair South African Molecular Pharming Conference 46
May 04, 2017: iBio Provides Corporate Update at Annual Shareholders Meeting 47
Appendix 49
Methodology 49
About GlobalData 49
Contact Us 49
Disclaimer 49

List of Tables
iBio Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
iBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
iBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
iBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
iBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
iBio Enters into Agreement with AzarGen Biotechnologies 13
Texas A&M University Enters into Agreement with iBio 14
iBio Amends Agreement with Medical University of South Carolina 15
Ibio Enters Into Agreement With GE Healthcare To Commercialize Plant-Based Technologies 16
iBio Enters into Agreement with Novici Biotech 17
iBio Amends Licensing Agreement with US University 18
iBio Enters into Licensing Agreement with University of Pittsburgh 19
iBio Enters Into Licensing Agreement With Caliber Biotherapeutics 20
iBio Enters into Licensing Agreement with Caliber Biotherapeutics 22
iBio Extends Licensing Agreement with Fraunhofer 23
iBio Extends its Licensing Agreement with Bio-Manguinhos 24
iBio Raises USD16 Million in Public Offering of Shares 25
iBio Raises USD4.5 Million in Public Offering of Shares 26
iBio to Raise Funds in Public Offering of Shares 27
iBio Raises USD1 Million in First Tranche of Private Placement of Shares 28
iBio Raises USD4 Million in Second and Final Tranche of Private Placement of Shares 30
iBio Raises USD2.2 Million in First Tranche of Private Placement of Shares 31
iBio Raises USD1 Million in Private Placement of Shares up on Exercise of Warrants 32
iBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 33
iBio Plans to Raise up to USD15 Million in Private Placement of Shares 34
iBio Raises USD10 Million in Private Placemet of Shares 35
iBio Raises USD0.5 Million in First Tranche of Private Placement of Shares 36
Ibio Completes Public Offering Of Units For US$4 Million 37
iBio, Biotechnology Company, Completes Public Offering Of Common Stock For US$10 Million 38
iBio Inc, Key Competitors 39
iBio Inc, Key Employees 40
iBio Inc, Other Locations 41
iBio Inc, Subsidiaries 41

List of Figures
iBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
iBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
iBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
iBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
iBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
iBio Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[iBio Inc (IBIO):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mylan N.V.:企業の戦略・SWOT・財務分析
    Mylan N.V. - Strategy, SWOT and Corporate Finance Report Summary Mylan N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Concordia International Rx UK Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Concordia International Rx UK Ltd (Concordia International), formerly Amdipharm Mercury Company Ltd, a subsidiary of Concordia International Corp, is a manufacturer of pharmaceutical products and orphan drugs. The company’s products include acetazolamide, adenosine, adrenaline acid tartrate, …
  • Services Group of America:企業の戦略・SWOT・財務分析
    Services Group of America - Strategy, SWOT and Corporate Finance Report Summary Services Group of America - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Vericel Corp (VCEL):企業の財務・戦略的SWOT分析
    Vericel Corp (VCEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Allahabad Bank (ALBK)
    Allahabad Bank (ALBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Adamis Pharmaceuticals Corp (ADMP):企業の財務・戦略的SWOT分析
    Summary Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc, is a biopharmaceutical company that develops therapies in areas of respiratory disease and allergy. The company offers pipeline product, epinephrine pre-filled syringe is developed for anaphylactic reactions such as …
  • Hammond Manufacturing Company Ltd (HMM.A):企業の財務・戦略的SWOT分析
    Summary Hammond Manufacturing Company Ltd (Hammond) is a power company that develops, manufactures and distributes electrical and electronic devices. The company offers electrical enclosures, small enclosures, racks and rack cabinets, outlet strips, transformers, and chokes and reactors. Its transfo …
  • Breckenridge Pharmaceutical Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Breckenridge Pharmaceutical Inc (Breckenridge), a subsidiary of Laboratorios Del Dr Esteve SA, is a healthcare solution provider that research, develops and markets various generic prescription products. The company offers products such as stradiol, oxcarbazepine tablets, methylprednisolone, …
  • Hanger, Inc. (HNGR)
    Hanger, Inc. (HNGR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Nahar Industrial Enterprises Limited (NAHARINDUS):企業の財務・戦略的SWOT分析
    Nahar Industrial Enterprises Limited (NAHARINDUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Greif, Inc.:企業の戦略・SWOT・財務情報
    Greif, Inc. - Strategy, SWOT and Corporate Finance Report Summary Greif, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Contact Energy Ltd:発電所・企業SWOT分析
    Contact Energy Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • SomaLogic Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary SomaLogic Inc (SomaLogic) is a life science company that discovers, develops and commercializes life science research tools and clinical diagnostic products. The company’s products include SOMAscan assay and SOMAmer reagents. Its SOMAscan reagents is a proteomic platform that combines the pr …
  • Puma Energy Holdings Pte Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Puma Energy Holdings Pte Ltd (Puma Energy) is an integrated midstream and downstream energy company. Its midstream operations include the supply, storage and transportation of petroleum products. The company’s downstream operations include the distribution, retail sales and wholesale of a wi …
  • Capcom Co Ltd (9697):企業の財務・戦略的SWOT分析
    Capcom Co Ltd (9697) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Hyundai Motor Co (005380)-エネルギー分野:企業M&A・提携分析
    Summary Hyundai Motor Company (Hyundai) is a global manufacturer of automobiles, which designs, develops and manufactures passenger and heavy duty automobiles and relevant parts. The company manufactures passenger cars under various brand names such as Centennial, Genesis, Veloster, Azera, Sonata, i …
  • Biocept Inc (BIOC):医療機器:M&Aディール及び事業提携情報
    Summary Biocept Inc (Biocept) is a molecular diagnostics company. The company develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. It offers assays for solid tumor indications, such as breast cancer, non-small cell l …
  • Plantic Technologies Ltd:企業の戦略的SWOT分析
    Plantic Technologies Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Mondelez International Inc (MDLZ):企業の財務・戦略的SWOT分析
    Mondelez International Inc (MDLZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Provogue (India) Limited (PROVOGE):企業の財務・戦略的SWOT分析
    Provogue (India) Limited (PROVOGE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆